Skip to main content

24-08-2016 | Prostate cancer | News | Article

News in brief

ADT not recommended for favourable-risk African–American prostate cancer patients

medwireNews: Exposure to even a short course of neoadjuvant androgen-deprivation therapy (ADT) has a deleterious effect on survival in African–American men with favourable-risk prostate cancer.

The US research team, therefore, recommends that “the use of ADT in [African–American] men should be reserved for treating higher risk [prostate cancer], for which level 1 evidence supports its use”.

As reported in Cancer, the chart review included 7272 prostate cancer patients with low-risk or favourable intermediate-risk disease who received brachytherapy either with or without neoadjuvant ADT for a median duration of 4 months.

Compared with non-African–African men treated with ADT, the risk of all-cause and other-cause mortality, but not prostate cancer-specific mortality, was significantly higher for African–African patients who received ADT, with adjusted hazard ratios of 1.77 and 1.86, respectively.

But this association between African–African ethnicity and mortality risk did not hold for those not given ADT, say Konstantin Kovtun (Brigham and Women’s Hospital–Dana-Farber Cancer Institute, Boston, Massachusetts) and fellow authors.

They emphasize, however, that their findings are hypothesis-generating and require validation in prospective studies.

By Shreeya Nanda

medwireNews is an independent medical news service provided by Springer Healthcare Limited. © Springer Healthcare Ltd; 2016

Related topics

See the research in context now

with trial summaries, expert opinion and congress coverage